Man Group
RVPH

Man Group’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Man Group’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,460
Closed -$253K – 2257
2023
Q4 		$253K Buy
+2,460
New +$221K ﹤0.01% 1858

Other funds holding RVPH

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
ECM
EMC Capital Management Houston, Texas $225M AUM 25.8% 1-Year Est. Return

Man Group's RVPH Position: Q1 2024 in Review

Man Group sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q1 2024, closing a stake of 2,460 shares — an estimated $253K sold.

Man Group first reported a position in RVPH in Q4 2023 and held it in 1 quarter. The position peaked at $253K in Q4 2023. 28 funds tracked by Wall St. Rank hold RVPH as of Q1 2024.

  • Man Group reported no remaining REVIVA PHARMA HLDGS INC position as of Q1 2024 after selling out during the quarter.
  • Man Group sold 2,460 REVIVA PHARMA HLDGS INC shares in Q1 2024, an estimated $253K.
  • Man Group first reported a position in REVIVA PHARMA HLDGS INC in Q4 2023 and held it in 1 quarter.
  • Man Group's REVIVA PHARMA HLDGS INC position peaked at $253K in Q4 2023.
  • 28 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.